<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>递送系统 on 知识铺的博客</title>
    <link>https://index.zshipu.com/geek/tags/%E9%80%92%E9%80%81%E7%B3%BB%E7%BB%9F/</link>
    <description>Recent content in 递送系统 on 知识铺的博客</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>zh-CN</language>
    <lastBuildDate>Mon, 31 Aug 2026 00:00:00 +0000</lastBuildDate>
    <atom:link href="https://index.zshipu.com/geek/tags/%E9%80%92%E9%80%81%E7%B3%BB%E7%BB%9F/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>mRNA肿瘤疫苗胜负手不在mRNA本身</title>
      <link>https://index.zshipu.com/geek/post/20260831/mRNA%E8%82%BF%E7%98%A4%E7%96%AB%E8%8B%97%E8%83%9C%E8%B4%9F%E6%89%8B%E4%B8%8D%E5%9C%A8mRNA%E6%9C%AC%E8%BA%AB/</link>
      <pubDate>Mon, 31 Aug 2026 00:00:00 +0000</pubDate>
      <guid>https://index.zshipu.com/geek/post/20260831/mRNA%E8%82%BF%E7%98%A4%E7%96%AB%E8%8B%97%E8%83%9C%E8%B4%9F%E6%89%8B%E4%B8%8D%E5%9C%A8mRNA%E6%9C%AC%E8%BA%AB/</guid>
      <description>mRNA肿瘤疫苗的胜负手不在mRNA。 临床试验结果反复指向，递送系统的入胞效率、肿瘤抗原的精准筛选以及对免疫微环境的调控，才是决定患者响应率和生存获益的核心变量。新王的逻辑正在从mRNA技术本身，转移到这些系统性瓶颈的解决上。 LNP递送效率成为首要制约因素 脂质纳米颗粒（LNP）是</description>
    </item>
  </channel>
</rss>
